4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzene-1-sulfonamide
| Title | Journal |
|---|---|
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | Chemical research in toxicology 20150518 |
| Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury. | Toxicological sciences : an official journal of the Society of Toxicology 20140101 |
| Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety. | Bioorganic & medicinal chemistry 20131001 |
| The effect of valdecoxib on the production of growth factors evoked by hypoxia and bacterial lipopolysaccharide in HMEC-1 cells. | Advances in clinical and experimental medicine : official organ Wroclaw Medical University 20130101 |
| Hypernociception and wound healing after application of cyanoacrylate ester as a tissue adhesive in rats. | Oral surgery, oral medicine, oral pathology and oral radiology 20121101 |
| Pain relief in laparoscopic cholecystectomy--a review of the current options. | Pain practice : the official journal of World Institute of Pain 20120701 |
| Pharmacokinetics of intravenous and intramuscular parecoxib in healthy Beagles. | Veterinary journal (London, England : 1997) 20120701 |
| Nonsteroidal anti-inflammatory drug-activated gene-1 plays a role in the impairing effects of cyclooxygenase inhibitors on gastric ulcer healing. | The Journal of pharmacology and experimental therapeutics 20120701 |
| Sulfonamides: a patent review (2008 - 2012). | Expert opinion on therapeutic patents 20120701 |
| A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. | Rheumatology international 20120601 |
| Development of a population pharmacokinetic model for parecoxib and its active metabolite valdecoxib after parenteral parecoxib administration in children. | Anesthesiology 20120501 |
| Nootropic activity of acetaminophen against colchicine induced cognitive impairment in rats. | Journal of clinical biochemistry and nutrition 20120501 |
| Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target. | Journal of medicinal chemistry 20120412 |
| Transfer of parecoxib and its primary active metabolite valdecoxib via transitional breastmilk following intravenous parecoxib use after cesarean delivery: a comparison of naive pooled data analysis and nonlinear mixed-effects modeling. | Anesthesia and analgesia 20120401 |
| Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold. | Journal of medicinal chemistry 20120308 |
| Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana. | Bioorganic & medicinal chemistry 20120215 |
| Diagnosis and treatment of acute ankle injuries: development of an evidence-based algorithm. | Orthopedic reviews 20120102 |
| Aspirin: pharmacology and clinical applications. | Thrombosis 20120101 |
| Do nonsteroidal anti-inflammatory drugs affect bone healing? A critical analysis. | TheScientificWorldJournal 20120101 |
| Challenging medical ghostwriting in US courts. | PLoS medicine 20120101 |
| Evaluation of uptake and transport of cationic and anionic ultrasmall iron oxide nanoparticles by human colon cells. | International journal of nanomedicine 20120101 |
| Non-steroidal anti-inflammatory drugs for the treatment of pain and immobility-associated osteoarthritis: consensus guidance for primary care. | BMC family practice 20120101 |
| A randomized, placebo-controlled double-blinded comparative clinical study of five over-the-counter non-pharmacological topical analgesics for myofascial pain: single session findings. | Chiropractic & manual therapies 20120101 |
| Inhibition of ion channels and heart beat in Drosophila by selective COX-2 inhibitor SC-791. | PloS one 20120101 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. | Chemical reviews 20111012 |
| Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II. | Bioorganic & medicinal chemistry letters 20111001 |
| Brain activity for chronic knee osteoarthritis: dissociating evoked pain from spontaneous pain. | European journal of pain (London, England) 20110901 |
| Simultaneous detection and quantification of parecoxib and valdecoxib in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. | Analytical and bioanalytical chemistry 20110901 |
| Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. | PLoS medicine 20110901 |
| Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates. | Bioorganic & medicinal chemistry 20110815 |
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | Journal of medicinal chemistry 20110714 |
| Defects in mouse nephrogenesis induced by selective and non-selective cyclooxygenase-2 inhibitors. | British journal of pharmacology 20110701 |
| 5-(3-Methyl-phen-yl)-3-phenyl-1,2-oxazole. | Acta crystallographica. Section E, Structure reports online 20110701 |
| Targeting oxidative stress, mitochondrial dysfunction and neuroinflammatory signaling by selective cyclooxygenase (COX)-2 inhibitors mitigates MPTP-induced neurotoxicity in mice. | Progress in neuro-psychopharmacology & biological psychiatry 20110601 |
| Synthesis and biological evaluation of loxoprofen derivatives. | Bioorganic & medicinal chemistry 20110601 |
| Iodocyclization of hydroxylamine derivatives based on the control of oxidative aromatization leading to 2,5-dihydroisoxazoles and isoxazoles. | The Journal of organic chemistry 20110506 |
| Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. | PLoS medicine 20110401 |
| A randomized controlled trial of valdecoxib and glyceryl trinitrate for the prevention of post-ERCP pancreatitis. | Journal of clinical gastroenterology 20110201 |
| Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. | Breast (Edinburgh, Scotland) 20110201 |
| A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth. | Bioorganic & medicinal chemistry 20110201 |
| Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata. | Bioorganic & medicinal chemistry letters 20110115 |
| A systematic review on the effectiveness of pharmacological interventions for chronic non-specific low-back pain. | European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 20110101 |
| Parecoxib and its metabolite valdecoxib directly interact with cannabinoid binding sites in CB1-expressing HEK 293 cells and rat brain tissue. | Neurochemistry international 20110101 |
| Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. | BMJ (Clinical research ed.) 20110101 |
| Animal products, diseases and drugs: a plea for better integration between agricultural sciences, human nutrition and human pharmacology. | Lipids in health and disease 20110101 |
| Methotrexate in atherogenesis and cholesterol metabolism. | Cholesterol 20110101 |
| Etoricoxibium picrate. | Acta crystallographica. Section E, Structure reports online 20110101 |
| Combined parecoxib and I.V. paracetamol provides additional analgesic effect with better postoperative satisfaction in patients undergoing anterior cruciate ligament reconstruction. | Saudi journal of anaesthesia 20110101 |
| Prostacyclin: an inflammatory paradox. | Frontiers in pharmacology 20110101 |
| The quest for targeted delivery in colon cancer: mucoadhesive valdecoxib microspheres. | International journal of nanomedicine 20110101 |
| Flavocoxid inhibits phospholipase A2, peroxidase moieties of the cyclooxygenases (COX), and 5-lipoxygenase, modifies COX-2 gene expression, and acts as an antioxidant. | Mediators of inflammation 20110101 |
| Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? | Frontiers in pharmacology 20110101 |
| [Novel iodocyclization method based on the controlling of oxidative aromatization]. | Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20110101 |
| Synthesis of Diarylpyrazoles Containing a Phenylsulphone or Carbonitrile Moiety and their Chalcones as Possible Anti-Inflammatory Agents. | Scientia pharmaceutica 20110101 |
| Dissofilm: a novel approach for delivery of phenobarbital; design and characterization. | Journal of young pharmacists : JYP 20110101 |
| Skeletal muscle protein metabolism in the elderly: Interventions to counteract the 'anabolic resistance' of ageing. | Nutrition & metabolism 20110101 |
| Spectrophotometric determination of tizanidine and orphenadrine via ion pair complex formation using eosin Y. | Chemistry Central journal 20110101 |
| Inhibition of HERG potassium channels by celecoxib and its mechanism. | PloS one 20110101 |
| Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review. | ISRN pharmacology 20110101 |
| Why we need easy access to all data from all clinical trials and how to accomplish it. | Trials 20110101 |
| An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect? | BMC public health 20110101 |
| Virtual screening of 2,3-disubstituted-4(3H)-quinazolinones possessing benzenesulfonamide moiety for COX-2 inhibitor. | Bioinformation 20110101 |
| Systematic review of herbals as potential anti-inflammatory agents: Recent advances, current clinical status and future perspectives. | Pharmacognosy reviews 20110101 |
| Autonomic status and pain profile in patients of chronic low back pain and following electro acupuncture therapy: a randomized control trial. | Indian journal of physiology and pharmacology 20110101 |
| Chronic inflammation in cancer development. | Frontiers in immunology 20110101 |
| Increased expression of cyclooxygenase-2 is associated with the progression to cirrhosis. | The Korean journal of internal medicine 20101201 |
| Reduction of N-hydroxy-sulfonamides, including N-hydroxy-valdecoxib, by the molybdenum-containing enzyme mARC. | Drug metabolism and disposition: the biological fate of chemicals 20101101 |
| Recent methodologies toward the synthesis of valdecoxib: a potential 3,4-diarylisoxazolyl COX-II inhibitor. | European journal of medicinal chemistry 20101101 |
| Enthalpy relaxation studies of two structurally related amorphous drugs and their binary dispersions. | Drug development and industrial pharmacy 20101101 |
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. | Bioorganic & medicinal chemistry letters 20101101 |
| Does the use of non-steroidal anti-inflammatory drugs after cardiac surgery increase the risk of renal failure? | Interactive cardiovascular and thoracic surgery 20101001 |
| Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studies. | Protoplasma 20101001 |
| Short-term treatment with COX-2 inhibitors does not impair fracture healing. | Journal of investigative surgery : the official journal of the Academy of Surgical Research 20101001 |
| Bitter pills for drug companies. | BMJ (Clinical research ed.) 20100917 |
| Eudragit S-100 entrapped chitosan microspheres of valdecoxib for colon cancer. | Journal of materials science. Materials in medicine 20100901 |
| Interventions for pain during fixed orthodontic appliance therapy. A systematic review. | The Angle orthodontist 20100901 |
| Loxoprofen Sodium, a Non-Selective NSAID, Reduces Atherosclerosis in Mice by Reducing Inflammation. | Journal of clinical biochemistry and nutrition 20100901 |
| Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality? | Current hypertension reports 20100801 |
| tert-Butyl 3-(8-bromo-4H,10H-1,2-oxazolo[4,3-c][1]benzoxepin-10-yl)-2-methyl-1H-indole-1-carboxyl-ate. | Acta crystallographica. Section E, Structure reports online 20100801 |
| The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy. | Experimental neurology 20100701 |
| Biotransformation of valdecoxib by microbial cultures. | Journal of microbiology and biotechnology 20100401 |
| Synthesis and evaluation of paracetamol esters as novel fatty acid amide hydrolase inhibitors. | Journal of medicinal chemistry 20100311 |
| Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis. | Journal of medicinal chemistry 20100311 |
| Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the reduction of morphine-related side effects after major surgery: a systematic review. | Health technology assessment (Winchester, England) 20100301 |
| Proteomic analysis in NSAIDs-treated primary cardiomyocytes. | Journal of proteomics 20100210 |
| Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery--a pilot study. | Naunyn-Schmiedeberg's archives of pharmacology 20100201 |
| Protective effects of selective and non-selective cyclooxygenase inhibitors in an animal model of chronic stress. | Neuroscience bulletin 20100201 |
| [Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review]. | Drugs of today (Barcelona, Spain : 1998) 20100201 |
| Progress in COX-2 inhibitors: a journey so far. | Current medicinal chemistry 20100101 |
| Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT. | PloS one 20100101 |
| Nonsteroidal Anti-Inflammatory Drugs: A survey of practices and concerns of pediatric medical and surgical specialists and a summary of available safety data. | Pediatric rheumatology online journal 20100101 |
| The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. | International journal of cell biology 20100101 |
| Traumeel S for pain relief following hallux valgus surgery: a randomized controlled trial. | BMC clinical pharmacology 20100101 |
| Reporting bias in medical research - a narrative review. | Trials 20100101 |
| Etoricoxib--preemptive and postoperative analgesia (EPPA) in patients with laparotomy or thoracotomy--design and protocols. | Trials 20100101 |
| Design of group IIA secreted/synovial phospholipase A(2) inhibitors: an oxadiazolone derivative suppresses chondrocyte prostaglandin E(2) secretion. | PloS one 20100101 |
| Preparation and evaluation of transdermal plasters containing norfloxacin: a novel treatment for burn wound healing. | Eplasty 20100101 |
| Role of COX-2 in cough reflex sensitivity to inhaled capsaicin in patients with sinobronchial syndrome. | Cough (London, England) 20100101 |
| Clinical pharmacology and vascular risk. | The open neurology journal 20100101 |
| Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3. | Drug metabolism and pharmacokinetics 20100101 |
| Mathematical modeling of tuberculosis bacillary counts and cellular populations in the organs of infected mice. | PloS one 20100101 |
| Pharmacophore elucidation and molecular docking studies on 5-phenyl-1-(3-pyridyl)-1h-1,2,4-triazole-3-carboxylic acid derivatives as COX-2 inhibitors. | Scientia pharmaceutica 20100101 |
| Musculoskeletal pain: prescription of NSAID and weak opioid by primary health care physicians in Sweden 2004-2008 - a retrospective patient record review. | Journal of pain research 20100101 |
| Natural anti-inflammatory agents for pain relief. | Surgical neurology international 20100101 |
| COX-2 Inhibition by Use of Rofecoxib or High Dose Aspirin Enhances ADP-Induced Platelet Aggregation in Fresh Blood. | The open cardiovascular medicine journal 20100101 |
| Preparation and characterization of solid dispersions of carvedilol with PVP K30. | Research in pharmaceutical sciences 20100101 |
| Governance of conflicts of interest in postmarketing surveillance research and the Canadian Drug Safety and Effectiveness Network. | Open medicine : a peer-reviewed, independent, open-access journal 20100101 |
| Risk of Upper Gastrointestinal Bleeding in a Cohort of New Users of Low-Dose ASA for Secondary Prevention of Cardiovascular Outcomes. | Frontiers in pharmacology 20100101 |
| Analgesic, anticonvulsant and anti-inflammatory activities of some synthesized benzodiazipine, triazolopyrimidine and bis-imide derivatives. | European journal of medicinal chemistry 20091201 |
| NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib. | Pharmacoepidemiology and drug safety 20091201 |
| Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c. | Bioorganic & medicinal chemistry letters 20091201 |
| Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. | Journal of hypertension 20091201 |
| A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example. | PLoS medicine 20091201 |
| Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. | Pharmacoepidemiology and drug safety 20091101 |
| Drug loaded poly[Lac(Glc-Leu)] microparticles: formulation and release characteristics. | Colloids and surfaces. B, Biointerfaces 20091101 |
| Parecoxib has non-significant long-term effects on bone healing in rats when administered for a short period after fracture. | Archives of orthopaedic and trauma surgery 20091001 |
| Cellular membranes function as a storage compartment for celecoxib. | Journal of molecular medicine (Berlin, Germany) 20091001 |
| Pharmacokinetics of intramuscular microparticle depot of valdecoxib in an experimental model. | Drug development and industrial pharmacy 20090901 |
| The search for new COX-2 inhibitors: a review of 2002 - 2008 patents. | Expert opinion on therapeutic patents 20090901 |
| Eggshell membrane in the treatment of pain and stiffness from osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled clinical study. | Clinical rheumatology 20090801 |
| Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors. | Bioorganic & medicinal chemistry letters 20090801 |
| The regulatory effect of the p38 signaling pathway on valdecoxib-induced apoptosis of the Eca109 cell line. | Oncology reports 20090801 |
| Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. | Bioorganic & medicinal chemistry 20090715 |
| Prolonged opportunity for neuroprotection in experimental stroke with selective blockade of cyclooxygenase-2 activity. | Brain research 20090707 |
| Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides. | Bioorganic & medicinal chemistry 20090701 |
| Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome. | PLoS computational biology 20090701 |
| Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? | Expert opinion on drug metabolism & toxicology 20090601 |
| Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis. | Journal of medicinal chemistry 20090514 |
| Effects of cyclooxygenase inhibition on anastomotic healing following large bowel resection in a rabbit model--a randomized, blinded, placebo-controlled trial. | International journal of colorectal disease 20090501 |
| Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate. | Journal of medicinal chemistry 20090423 |
| Validation of single isocratic HPLC method for the assay of valdecoxib and determination of metaisomer impurity. | Journal of chromatographic science 20090401 |
| Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. | Annals of the rheumatic diseases 20090301 |
| Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates. | Bioorganic & medicinal chemistry 20090201 |
| Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data. | Anesthesia and analgesia 20090101 |
| A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis. | Osteopathic medicine and primary care 20090101 |
| A natural seaweed derived mineral supplement (Aquamin F) for knee osteoarthritis: a randomised, placebo controlled pilot study. | Nutrition journal 20090101 |
| Complexation of cox-2 inhibitors with bovine serum albumin: interaction mechanism. | Pharmaceutical development and technology 20090101 |
| Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs. | BMC clinical pharmacology 20090101 |
| Anti-inflammatory and antiarthritic effects of piperine in human interleukin 1beta-stimulated fibroblast-like synoviocytes and in rat arthritis models. | Arthritis research & therapy 20090101 |
| Obesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorship. | PloS one 20090101 |
| Competition between COX-2 inhibitors and some other drugs for binding sites on human serum albumin. | Drug metabolism and drug interactions 20090101 |
| Prophylaxis of heterotopic ossification - an updated review. | Journal of orthopaedic surgery and research 20090101 |
| Treatment and chemoprevention of NSAID-associated gastrointestinal complications. | Therapeutics and clinical risk management 20090101 |
| Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale. | PloS one 20090101 |
| Development of mucoadhesive buccal films for the treatment of oral sub-mucous fibrosis: a preliminary study. | Pharmaceutical development and technology 20090101 |
| Discrepancy among observational studies: example of naproxen-associated adverse events. | The open rheumatology journal 20090101 |
| Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. | BMJ (Clinical research ed.) 20090101 |
| Reduction in opioid-related adverse events and improvement in function with parecoxib followed by valdecoxib treatment after non-cardiac surgery: a randomized, double-blind, placebo-controlled, parallel-group trial. | Clinical drug investigation 20090101 |
| Multiparameter phospho-flow analysis of lymphocytes in early rheumatoid arthritis: implications for diagnosis and monitoring drug therapy. | PloS one 20090101 |
| Identification of the specific binding proteins of bioactive small compound using affinity resins. | Methods in molecular biology (Clifton, N.J.) 20090101 |
| Drugs associated with more suicidal ideations are also associated with more suicide attempts. | PloS one 20090101 |
| Celecoxib in arthritis: relative risk management profile and implications for patients. | Therapeutics and clinical risk management 20090101 |
| Drug-induced hematologic syndromes. | Advances in hematology 20090101 |
| Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. | Drug, healthcare and patient safety 20090101 |
| Co-relationship of physical stability of amorphous dispersions with enthalpy relaxation. | Die Pharmazie 20081101 |
| Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib. | Pharmacoepidemiology and drug safety 20081001 |
| Risk management profile of etoricoxib: an example of personalized medicine. | Therapeutics and clinical risk management 20081001 |
| Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity. | Journal of medicinal chemistry 20080814 |
| Thermodynamic behavior of glassy state of structurally related compounds. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20080801 |
| Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. | Trends in pharmacological sciences 20080801 |
| A postgenomic integrated view of prostaglandins in reproduction: implications for other body systems. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20080801 |
| Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20080801 |
| The anti-proliferative potency of celecoxib is not a class effect of coxibs. | Biochemical pharmacology 20080715 |
| [American judge preserves confidentiality in the peer review process]. | Nederlands tijdschrift voor geneeskunde 20080712 |
| Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. | Stroke 20080701 |
| Effects of a non-selective COX inhibitor and selective COX-2 inhibitors on contractility of human and porcine ureters in vitro and in vivo. | British journal of pharmacology 20080701 |
| Comparison of parecoxib and proparacetamol in endoscopic nasal surgery patients. | Yonsei medical journal 20080630 |
| Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and chronic pain. | Clinical pharmacology and therapeutics 20080601 |
| Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of zafirlukast, a selective leukotriene antagonist in human plasma: application to a clinical pharmacokinetic study. | Biomedical chromatography : BMC 20080601 |
| Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. | Pharmacoepidemiology and drug safety 20080601 |
| Multimodal analgesia without parenteral narcotics for total knee arthroplasty. | The Journal of arthroplasty 20080601 |
| Pharmaceutical particle engineering via spray drying. | Pharmaceutical research 20080501 |
| Chemical and biological investigation of N-hydroxy-valdecoxib: An active metabolite of valdecoxib. | Bioorganic & medicinal chemistry 20080501 |
| Effect of paracetamol and coxib with or without dexamethasone after laparoscopic cholecystectomy. | Acta anaesthesiologica Scandinavica 20080501 |
| Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. | Circulation research 20080425 |
| Preserving confidentiality in the peer review process. | JAMA 20080423 |
| Computer-aided, rational design of a potent and selective small peptide inhibitor of cyclooxygenase 2 (COX2). | Journal of biomolecular structure & dynamics 20080401 |
| Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. | Health technology assessment (Winchester, England) 20080401 |
| Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis. | Therapeutics and clinical risk management 20080401 |
| Crunch time for peer review in lawsuit. | Nature 20080306 |
| Intravenous parecoxib rapidly leads to COX-2 inhibitory concentration of valdecoxib in the central nervous system. | Clinical pharmacology and therapeutics 20080301 |
| Anti-inflammatory and analgesic activities of newly synthesized chiral peptide derivatives using (3-benzoyl- 4,5-dioxo-2-phenyl-pyrrolidin-1-yl)acetic acid ethyl ester as starting material. | Archiv der Pharmazie 20080301 |
| Informatic tools and approaches in postmarketing pharmacovigilance used by FDA. | The AAPS journal 20080301 |
| Biotransformation of valdecoxib by plant cell cultures. | Applied biochemistry and biotechnology 20080301 |
| Inhibition of delayed rectifier potassium channels and induction of arrhythmia: a novel effect of celecoxib and the mechanism underlying it. | The Journal of biological chemistry 20080118 |
| Celecoxib transiently inhibits cellular protein synthesis. | Biochemical pharmacology 20080115 |
| New celecoxib derivatives as anti-inflammatory agents. | Journal of medicinal chemistry 20080110 |
| Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. | European journal of pharmacology 20080106 |
| Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans. | Clinical biochemistry 20080101 |
| Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. | Expert opinion on drug safety 20080101 |
| Etoricoxib-induced erythema-multiforme-like eruption. | Dermatology (Basel, Switzerland) 20080101 |
| Use of cox-2 inhibitors in patients with retinal venous occlusive disease. | Retina (Philadelphia, Pa.) 20080101 |
| Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. | Arthritis research & therapy 20080101 |
| What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs. | Arthritis research & therapy 20080101 |
| OTC analgesics and drug interactions: clinical implications. | Osteopathic medicine and primary care 20080101 |
| A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized controlled pilot trial. | Nutrition journal 20080101 |
| Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis. | BMC musculoskeletal disorders 20080101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080101 |
| Activation of interleukin-32 pro-inflammatory pathway in response to influenza A virus infection. | PloS one 20080101 |
| Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports. | Arthritis research & therapy 20080101 |
| Patients with rheumatoid arthritis have an altered circulatory aggrecan profile. | BMC musculoskeletal disorders 20080101 |
| Perioperative celecoxib administration for pain management after total knee arthroplasty - a randomized, controlled study. | BMC musculoskeletal disorders 20080101 |
| Peroxisome proliferator-activated receptors and progression of colorectal cancer. | PPAR research 20080101 |
| Virtual screening for novel COX-2 inhibitors using the ZINC database. | Bioinformation 20080101 |
| Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. | BMC cancer 20080101 |
| Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. | Arthritis research & therapy 20080101 |
| Role of nitric oxide in the gastrointestinal tract. | Arthritis research & therapy 20080101 |
| Frankincense: systematic review. | BMJ (Clinical research ed.) 20080101 |
| PPAR-delta in Vascular Pathophysiology. | PPAR research 20080101 |
| [Cardiovascular risk of cyclooxygenase selective inhibitors]. | Revista medica del Instituto Mexicano del Seguro Social 20080101 |
| Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung Cancer. | PPAR research 20080101 |
| FTIR studies on differential intermolecular association in crystalline and amorphous states of structurally related non-steroidal anti-inflammatory drugs. | Molecular pharmaceutics 20080101 |
| Optimization of fast dissolving etoricoxib tablets prepared by sublimation technique. | Indian journal of pharmaceutical sciences 20080101 |
| An overview of the articles published in the Indian Journal of Pharmacology during the year 2007. | Indian journal of pharmacology 20080101 |
| The synthesis of highly substituted isoxazoles by electrophilic cyclization: an efficient synthesis of valdecoxib. | The Journal of organic chemistry 20071207 |
| Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. | British journal of cancer 20071203 |
| Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. | Bioorganic & medicinal chemistry 20071201 |
| Early detection of adverse drug events within population-based health networks: application of sequential testing methods. | Pharmacoepidemiology and drug safety 20071201 |
| NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20071201 |
| COX-2 inhibitors and postoperative ileus. | Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 20071101 |
| Roles of vasoconstrictor prostaglandins, COX-1 and -2, and AT1, AT2, and TP receptors in a rat model of early 2K,1C hypertension. | American journal of physiology. Heart and circulatory physiology 20071101 |
| Cardiovascular effects of cyclooxygenase-2 inhibitors. | Current opinion in gastroenterology 20071101 |
| Successful treatment of cystoid macular edema with valdecoxib. | Journal of cataract and refractive surgery 20071101 |
| Covalent binding of rofecoxib, but not other cyclooxygenase-2 inhibitors, to allysine aldehyde in elastin of human aorta. | Drug metabolism and disposition: the biological fate of chemicals 20071001 |
| Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal. | Nature clinical practice. Rheumatology 20071001 |
| Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice? | Therapeutics and clinical risk management 20071001 |
| The ubiquitin- and proteasome-dependent degradation of COX-2 is regulated by the COP9 signalosome and differentially influenced by coxibs. | Journal of molecular medicine (Berlin, Germany) 20070901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20070901 |
| The effects of common anti-inflammatory drugs on the healing rat patellar tendon. | The American journal of sports medicine 20070801 |
| Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. | Current medical research and opinion 20070801 |
| The selective and non-selective cyclooxygenase inhibitors valdecoxib and piroxicam induce the same postoperative analgesia and control of trismus and swelling after lower third molar removal. | Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20070801 |
| Clinical pharmacology of celecoxib, a COX-2 selective inhibitor. | Expert opinion on pharmacotherapy 20070801 |
| Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond. | Acta bio-medica : Atenei Parmensis 20070801 |
| Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. | Cardiovascular research 20070715 |
| Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. | Pharmacoepidemiology and drug safety 20070701 |
| Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature. | Archives of dermatological research 20070701 |
| Utility and sensitivity of the sore throat pain model: results of a randomized controlled trial on the COX-2 selective inhibitor valdecoxib. | Journal of clinical pharmacology 20070701 |
| Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20070701 |
| [Cardiovascular toxicity of selective COX-2-inhibitors and classical NSAIDs]. | Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS 20070701 |
| Polyamines in inflammation and their modulation by conventional anti-inflammatory drugs. | Indian journal of experimental biology 20070701 |
| Topical dosage form of valdecoxib: preparation and pharmacological evaluation. | Acta pharmaceutica (Zagreb, Croatia) 20070601 |
| Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. | Fundamental & clinical pharmacology 20070601 |
| Preliminary development of a responder index for chronic low back pain. | The Journal of rheumatology 20070601 |
| Multimodal analgesia for radical prostatectomy provides better analgesia and shortens hospital stay. | Journal of clinical anesthesia 20070601 |
| Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis. | Archives of dermatology 20070601 |
| Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study. | Clinical therapeutics 20070601 |
| Current aproach to cancer pain management: Availability and implications of different treatment options. | Therapeutics and clinical risk management 20070601 |
| Targeting inhibition of COX-2: a review of patents, 2002-2006. | Recent patents on inflammation & allergy drug discovery 20070601 |
| Successful treatment of cystoid macular edema with valdecoxib. | Journal of cataract and refractive surgery 20070401 |
| Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. | Molecular cancer therapeutics 20070401 |
| Cyclooxygenase-2 inhibition increases gastric tone and delays gastric emptying in rats. | Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20070301 |
| Dynamic simulations on the arachidonic acid metabolic network. | PLoS computational biology 20070301 |
| Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction. | Circulation 20070123 |
| Pharmacodynamic of cyclooxygenase inhibitors in humans. | Prostaglandins & other lipid mediators 20070101 |
| Prospective randomized, double-blind, placebo-controlled study of pre- and postoperative administration of a COX-2-specific inhibitor as opioid-sparing analgesia in major colorectal surgery. | Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 20070101 |
| Safety of parecoxib and valdecoxib after noncardiac surgery: lack of demonstration. | Anesthesiology 20070101 |
| Selective and nonselective cyclooxygenase-2 inhibitors and experimental fracture-healing. Reversibility of effects after short-term treatment. | The Journal of bone and joint surgery. American volume 20070101 |
| Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk. | Arthritis research & therapy 20070101 |
| Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. | Current topics in medicinal chemistry 20070101 |
| Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. | The Clinical journal of pain 20070101 |
| Dual carbonic anhydrase--cyclooxygenase-2 inhibitors. | Current topics in medicinal chemistry 20070101 |
| New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors: focus on use in the elderly. | Drugs & aging 20070101 |
| Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. | International journal of biological sciences 20070101 |
| COX-2 inhibitors and cardiovascular risk. | Sub-cellular biochemistry 20070101 |
| Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. | BMC musculoskeletal disorders 20070101 |
| Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. | BMC psychiatry 20070101 |
| Preparation and properties of valdecoxib-hydroxypropyl beta-cyclodextrin inclusion complex. | PDA journal of pharmaceutical science and technology 20070101 |
| The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. | PloS one 20070101 |
| Molecular and thermodynamic aspects of solubility advantage from solid dispersions. | Molecular pharmaceutics 20070101 |
| An effective dose of valdecoxib in experimental mouse models of pain. | Methods and findings in experimental and clinical pharmacology 20070101 |
| Apoptosis is not the major death mechanism induced by celecoxib on rheumatoid arthritis synovial fibroblasts. | Arthritis research & therapy 20070101 |
| Multi-modal-analgesia for pain management after Hallux Valgus surgery: a prospective randomised study on the effect of ankle block. | Journal of orthopaedic surgery and research 20070101 |
| Protective effect of non-selective and selective COX-2-inhibitors in acute immobilization stress-induced behavioral and biochemical alterations. | Pharmacological reports : PR 20070101 |
| Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs. | Current pharmaceutical design 20070101 |
| Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis. | Core evidence 20070101 |
| Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats. | European journal of pharmacology 20061203 |
| Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. | Pharmacoepidemiology and drug safety 20061201 |
| Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. | Journal of clinical pharmacy and therapeutics 20061201 |
| An analgesic model for assessment of acute pain response in osteoarthritis of the knee. | Osteoarthritis and cartilage 20061101 |
| Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). | PLoS clinical trials 20061101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20061101 |
| Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. | JAMA 20061004 |
| [Analgesia in colon surgery. Can the use of NSAIDs reduce the opioid consumption following conventional and laparoscopic interventions?]. | Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20061001 |
| Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals. | Die Pharmazie 20061001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20061001 |
| Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen. | Harvard heart letter : from Harvard Medical School 20061001 |
| Valdecoxib for postoperative pain management after cesarean delivery: a randomized, double-blind, placebo-controlled study. | Anesthesia and analgesia 20060901 |
| Formulation and evaluation of Nanostructured Lipid Carrier (NLC)-based gel of Valdecoxib. | Drug development and industrial pharmacy 20060901 |
| Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. | International journal of clinical pharmacology and therapeutics 20060901 |
| Impact of cyclooxygenase inhibitors in the Women's Health Initiative hormone trials: secondary analysis of a randomized trial. | PLoS clinical trials 20060901 |
| Enhancement of dissolution profile by solid dispersion (kneading) technique. | AAPS PharmSciTech 20060901 |
| [What do we know about the cardiovascular toxicity of the NSAIDs?]. | Presse medicale (Paris, France : 1983) 20060901 |
| [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]. | Presse medicale (Paris, France : 1983) 20060901 |
| Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. | Vascular health and risk management 20060901 |
| [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]. | Presse medicale (Paris, France : 1983) 20060901 |
| Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. | Circulation 20060829 |
| COX-2 inhibitors and early failure of free vascular flaps. | The New England journal of medicine 20060803 |
| Constitutive cyclo-oxygenase-2 does not contribute to the development of human visceral pain hypersensitivity. | European journal of pain (London, England) 20060801 |
| Reversible binding of celecoxib and valdecoxib with human serum albumin using fluorescence spectroscopic technique. | Pharmacological research 20060801 |
| Selective cyclooxygenase inhibition: its role in pain and anaesthesia. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20060801 |
| The COX-2 inhibitors--an update. | American heart journal 20060801 |
| Preparation, characterization and in vitro dissolution studies of solid systems of valdecoxib with chitosan. | Chemical & pharmaceutical bulletin 20060801 |
| How specific are 'target-specific' drugs? Celecoxib as a case in point. | Molecular interventions 20060801 |
| NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. | European heart journal 20060701 |
| Forced-degradation study of valdecoxib as bulk drug and in tablet formulation by HPTLC. | Journal of separation science 20060701 |
| [Cyclooxygenase inhibitors: a never ending story?]. | Giornale italiano di cardiologia (2006) 20060701 |
| Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, placebo-controlled, single-dose studies. | Clinical therapeutics 20060701 |
| The COX-2 specific inhibitor Valdecoxib versus tramadol in acute ankle sprain: a multicenter randomized, controlled trial. | The American journal of sports medicine 20060601 |
| Getting it right: being smarter about clinical trials. | PLoS medicine 20060601 |
| Efficacy of a selective COX-2 inhibitor for controlling irregular uterine bleeding in DMPA users. | Contraception 20060601 |
| Synthesis of the pyrazole isostere of valdecoxib. | Die Pharmazie 20060601 |
| [Cyclooxygenase-2: a new therapeutic target in atherosclerosis?]. | Medicina clinica 20060527 |
| Prostaglandin I2 release following mesenteric traction during abdominal surgery is mediated by cyclooxygenase-1. | European journal of pharmacology 20060501 |
| Update on nonsteriodal anti-inflammatory drugs. | Current opinion in rheumatology 20060501 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. | Arthritis and rheumatism 20060501 |
| Valdecoxib exposures reported to Texas poison centers during 2002-2004. | Journal of toxicology and environmental health. Part A 20060501 |
| Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. | Circulation 20060425 |
| COX-2 inhibitors and pain after oral surgery - pertinent papers 2002-2003. | The British journal of oral & maxillofacial surgery 20060401 |
| Molecular dynamics simulations of arachidonic acid-derived pentadienyl radical intermediate complexes with COX-1 and COX-2: insights into oxygenation regio- and stereoselectivity. | Biochemistry 20060314 |
| Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. | Anesthesiology 20060301 |
| Evaluation of preemptive valdecoxib therapy on initial archwire placement discomfort in adults. | The Angle orthodontist 20060301 |
| Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study. | Die Pharmazie 20060301 |
| A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years. | Clinical therapeutics 20060301 |
| Etoricoxib for arthritis and pain management. | Therapeutics and clinical risk management 20060301 |
| COX inhibitors and breast cancer. | British journal of cancer 20060213 |
| Ocular adverse effects associated with cyclooxygenase-2 inhibitors. | Archives of ophthalmology (Chicago, Ill. : 1960) 20060201 |
| A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms. | Clinical therapeutics 20060201 |
| Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II 'selective' inhibitor celecoxib. | Bioorganic & medicinal chemistry letters 20060115 |
| Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. | Biomedical chromatography : BMC 20060101 |
| Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients? | Alimentary pharmacology & therapeutics 20060101 |
| Spray dried excipient base: a novel technique for the formulation of orally disintegrating tablets. | Chemical & pharmaceutical bulletin 20060101 |
| Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. | BMC cancer 20060101 |
| NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. | Drug safety 20060101 |
| First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]. | Arthritis research & therapy 20060101 |
| Effect of valdecoxib pretreatment on pain and secondary hyperalgesia: a randomized controlled trial in healthy volunteers [ISRCTN05282752, NCT00260325]. | BMC anesthesiology 20060101 |
| Coxibs and cardiovascular side-effects: from light to shadow. | Current pharmaceutical design 20060101 |
| Do coxibs reduce prescription of gastroprotective agents? Results of a record linkage study. | Cost effectiveness and resource allocation : C/E 20060101 |
| Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. | Journal of neuroinflammation 20060101 |
| Cyclooxygenase expression is not required for release of arachidonic acid from cells by some nonsteroidal anti-inflammatory drugs and cancer preventive agents. | BMC pharmacology 20060101 |
| Disseminating drug prescribing information: the cox-2 inhibitors withdrawals. | Journal of the American Medical Informatics Association : JAMIA 20060101 |
| Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. | Molecular cancer 20060101 |
| Update on guidelines for the treatment of chronic musculoskeletal pain. | Clinical rheumatology 20060101 |
| Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity. | Journal of cardiovascular pharmacology 20060101 |
| Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases. | Drugs 20060101 |
| Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. | Drug safety 20060101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20060101 |
| Analgesic efficacy of valdecoxib for acute postoperative pain after bunionectomy. | Journal of the American Podiatric Medical Association 20060101 |
| Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. | Arthritis research & therapy 20060101 |
| Responding rapidly to FDA drug withdrawals: design and application of a new approach for a consumer health website. | Journal of medical Internet research 20060101 |
| Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. | BMC musculoskeletal disorders 20060101 |
| Impact of rofecoxib withdrawal on cyclooxygenase-2 utilization among patients with and without cardiovascular risk. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20060101 |
| Valdecoxib provides effective pain relief following acute ankle sprain. | The Journal of international medical research 20060101 |
| Parecoxib is neuroprotective in spontaneously hypertensive rats after transient middle cerebral artery occlusion: a divided treatment response? | Journal of neuroinflammation 20060101 |
| A case of intranasal meningocele. | McGill journal of medicine : MJM : an international forum for the advancement of medical sciences by students 20060101 |
| What clinical pharmacology means to us. | Mens sana monographs 20060101 |
| Topical analgesia for chest tube removal in cardiac patients. | Journal of cardiothoracic and vascular anesthesia 20051201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20051201 |
| More bad news about anti-inflammatory agents. | Journal of medical toxicology : official journal of the American College of Medical Toxicology 20051201 |
| Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis. | The New Zealand medical journal 20051125 |
| Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? | Drug metabolism and disposition: the biological fate of chemicals 20051101 |
| Synthesis of 4-(5-[18F]fluoromethyl-3-phenylisoxazol-4-yl)benzenesulfonamide, a new [18F]fluorinated analogue of valdecoxib, as a potential radiotracer for imaging cyclooxygenase-2 with positron emission tomography. | Bioorganic & medicinal chemistry letters 20051101 |
| Celecoxib and cardiovascular risks. | Expert opinion on drug safety 20051101 |
| COX-2 inhibitors and the heart: putting risk in perspective. | Advance for nurse practitioners 20051101 |
| Cardiovascular issues of COX-2 inhibitors and NSAIDs. | Australian family physician 20051101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20051101 |
| [Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs)]. | Deutsche medizinische Wochenschrift (1946) 20051007 |
| Cancer chemoprevention: lessons learned and future directions. | British journal of cancer 20051003 |
| Valdecoxib for treatment of a single, acute, moderate to severe migraine headache. | Headache 20051001 |
| Prescriptions for chronic high-dose cyclooxygenase-2 inhibitors are often inappropriate and potentially dangerous. | Journal of general internal medicine 20051001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20051001 |
| How celecoxib could be safer, how valdecoxib might have been. | The Annals of pharmacotherapy 20050901 |
| Synthesis and reactions of some new substituted pyridine and pyrimidine derivatives as analgesic, anticonvulsant and antiparkinsonian agents. | Archiv der Pharmazie 20050901 |
| Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications. | Journal (Canadian Dental Association) 20050901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050901 |
| COX-2 inhibition and pain management: a review summary. | Expert review of clinical immunology 20050901 |
| Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis. | Arthritis and rheumatism 20050815 |
| Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray? | Current medical research and opinion 20050801 |
| Monocyte cyclooxygenase-2 activity: a new therapeutic target for atherosclerosis? | Current drug targets. Cardiovascular & haematological disorders 20050801 |
| Further action taken on COX 2 inhibitors in Europe. | BMJ (Clinical research ed.) 20050702 |
| Pulmonary embolism in a woman taking oral contraceptives and valdecoxib. | PLoS medicine 20050701 |
| Cyclooxygenase-2 inhibitors: a new therapeutic option in the treatment of macular edema after cataract surgery. | Journal of cataract and refractive surgery 20050701 |
| An evaluation of preemptive valdecoxib therapy on discomfort caused by initial archwire placement in adult orthodontic patients. | Texas dental journal 20050701 |
| Effect of selective cyclooxygenase-2 inhibitors on heart rate in healthy young men. | The American journal of cardiology 20050615 |
| Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological fluids. | Biomedical chromatography : BMC 20050601 |
| The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor. | European journal of clinical pharmacology 20050601 |
| Rescuing COX-2 inhibitors from the waste bin. | Journal of the National Cancer Institute 20050601 |
| Valdecoxib withdrawal leaves pain relief treatment gap. | Gastroenterology 20050601 |
| The meaning of pain relief in a clinical trial. | The journal of pain : official journal of the American Pain Society 20050601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050601 |
| Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. | Vascular health and risk management 20050601 |
| FDA ponders future of NSAIDs: Pfizer reluctantly withdraws Bextra. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050515 |
| New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20050510 |
| Valdecoxib-associated acute generalized exanthematous pustulosis. | Burns : journal of the International Society for Burn Injuries 20050501 |
| Vioxx, Celebrex, Bextra....do we have a new target for anti-inflammatory and antipyretic therapy? | American journal of physiology. Regulatory, integrative and comparative physiology 20050501 |
| Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis. | The American journal of gastroenterology 20050501 |
| Cyclodextrin complexes of valdecoxib: properties and anti-inflammatory activity in rat. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20050501 |
| COX-2-selective inhibitor valdecoxib induces severe allergic skin reactions. | The Journal of allergy and clinical immunology 20050501 |
| Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20050501 |
| [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions]. | Zeitschrift fur Rheumatologie 20050501 |
| Pfizer withdraws Bextra in South Africa. | South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20050501 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050501 |
| Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention. | Journal of the National Cancer Institute 20050420 |
| Another popular painkiller gets the government's hook. | U.S. news & world report 20050418 |
| Pfizer is asked to suspend sales of painkiller. | BMJ (Clinical research ed.) 20050416 |
| [COX-2 inhibitors--one step forward and two steps back]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20050407 |
| Exacerbation of carpal tunnel syndrome under treatment with valdecoxib. | Anesthesia and analgesia 20050401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050401 |
| Valdecoxib: cutaneous and vascular risks. | Prescrire international 20050401 |
| Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor. | Expert opinion on investigational drugs 20050401 |
| Raising the safety bar--the FDA's coxib meeting. | The New England journal of medicine 20050331 |
| Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. | The New England journal of medicine 20050317 |
| COX-2 inhibitors--lessons in drug safety. | The New England journal of medicine 20050317 |
| COX-2 inhibitors--a lesson in unexpected problems. | The New England journal of medicine 20050317 |
| A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma. | Biomedical chromatography : BMC 20050301 |
| Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. | The Journal of pharmacology and experimental therapeutics 20050301 |
| Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. | Alimentary pharmacology & therapeutics 20050301 |
| COX-2 inhibitor induced anuric renal failure in a previously healthy young woman. | Clinical nephrology 20050301 |
| Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks. | Harvard health letter 20050301 |
| Coxibs: can this class of drugs survive? | Vascular health and risk management 20050301 |
| Drug safety. FDA panel urges caution on many anti-inflammatory drugs. | Science (New York, N.Y.) 20050225 |
| Vioxx may go back on sale after scraping past FDA panel. | Nature 20050224 |
| Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. | Bioorganic & medicinal chemistry letters 20050215 |
| Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. | Cardiovascular research 20050201 |
| The cyclooxygenase-2-specific inhibitor parecoxib sodium is as effective as 12 mg of morphine administered intramuscularly for treating pain after gynecologic laparotomy surgery. | Anesthesia and analgesia 20050201 |
| Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. | Anesthesiology 20050201 |
| Reduction of opioid-related adverse events using opioid-sparing analgesia with COX-2 inhibitors lacks documentation: a systematic review. | Acta anaesthesiologica Scandinavica 20050201 |
| Current concepts in nonoperative management of knee osteoarthritis. | Orthopedics 20050201 |
| Parecoxib, valdecoxib, and cardiovascular risk. | Circulation 20050125 |
| Arthritis medicines and cardiovascular events--'house of coxibs'. | JAMA 20050119 |
| Role of cyclooxygenase-2 in lipopolysaccharide-induced hyperalgesia in formalin test. | Indian journal of experimental biology 20050101 |
| Valdecoxib for treatment of primary dysmenorrhea. A randomized, double-blind comparison with placebo and naproxen. | Journal of general internal medicine 20050101 |
| Valdecoxib-induced systemic contact dermatitis confirmed by positive patch test. | Contact dermatitis 20050101 |
| Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20050101 |
| Enhancement of dissolution rate of valdecoxib using solid dispersions with polyethylene glycol 4000. | Drug development and industrial pharmacy 20050101 |
| Do selective cyclo-oxygenase-2 inhibitors have a future? | Drug safety 20050101 |
| Sentence ordered in drug counterfeiting case. | FDA consumer 20050101 |
| Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly? | Drugs & aging 20050101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050101 |
| Valdecoxib for the management of chronic and acute pain. | Expert review of neurotherapeutics 20050101 |
| Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. | Arthritis research & therapy 20050101 |
| SuperLigands - a database of ligand structures derived from the Protein Data Bank. | BMC bioinformatics 20050101 |
| Relative thromboembolic risks associated with COX-2 inhibitors. | The Annals of pharmacotherapy 20050101 |
| COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective. | Current topics in medicinal chemistry 20050101 |
| Impact of COX-2 inhibitors in common clinical practice a gastroenterologist's perspective. | Current topics in medicinal chemistry 20050101 |
| Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex. | Yale journal of health policy, law, and ethics 20050101 |
| Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886]. | BMC musculoskeletal disorders 20050101 |
| FDA announces changes affecting the marketing of non-steroidal anti-inflammatory drugs. | FDA consumer 20050101 |
| Current state of therapy for pain and inflammation. | Arthritis research & therapy 20050101 |
| Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. | Arthritis research & therapy 20050101 |
| Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs. | Arthritis research & therapy 20050101 |
| Balancing the gastrointestinal benefits and risks of nonselective NSAIDs. | Arthritis research & therapy 20050101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050101 |
| Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. | Drug safety 20050101 |
| Cardiovascular complications of non-steroidal anti-inflammatory drugs. | Annals of clinical and laboratory science 20050101 |
| [Cyclooxygenase-2 inhibitors and the ethics of research]. | Medicina 20050101 |
| The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. | Pharmacological reports : PR 20050101 |
| COX-2 inhibitors and heart. | Indian heart journal 20050101 |
| Concern about one drug or entire class of drugs. | Reumatizam 20050101 |
| COX-2 selective inhibitors and heart health. | Postgraduate medicine 20050101 |
| Cardiovascular toxicity of valdecoxib. | The New England journal of medicine 20041223 |
| Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides. | Bioorganic & medicinal chemistry letters 20041220 |
| ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor. | The Journal of pharmacology and experimental therapeutics 20041201 |
| Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. | Atherosclerosis 20041201 |
| Comparison of valdecoxib and an oxycodone-acetaminophen combination for acute musculoskeletal pain in the emergency department: a randomized controlled trial. | Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 20041201 |
| Serious dermatologic reaction associated with valdecoxib: report of two cases. | Journal of the American Academy of Dermatology 20041201 |
| [The specific cox-2 inhibitor valdecoxib provides effective analgesia after inguinal hernia surgery]. | Revista espanola de anestesiologia y reanimacion 20041201 |
| Could Bextra increase heart risks too? | Health news (Waltham, Mass.) 20041201 |
| A painkiller is pulled from the market. So what do you do now? | Heart advisor 20041201 |
| Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors. | Bioorganic & medicinal chemistry letters 20041101 |
| Pfizer criticised over delay in admitting drug's problems. | BMJ (Clinical research ed.) 20041023 |
| Coxibs and cardiovascular disease. | The New England journal of medicine 20041021 |
| Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects. | Acta anaesthesiologica Scandinavica 20041001 |
| Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. | Pain 20041001 |
| The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II. | Inflammation 20041001 |
| Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. | Journal of medicinal chemistry 20040923 |
| Stability study of amorphous valdecoxib. | International journal of pharmaceutics 20040910 |
| Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. | Alimentary pharmacology & therapeutics 20040901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040901 |
| First and second generations of COX-2 selective inhibitors. | Mini reviews in medicinal chemistry 20040801 |
| COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. | Mini reviews in medicinal chemistry 20040801 |
| Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial. | Clinical therapeutics 20040801 |
| Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design. | Bioorganic & medicinal chemistry letters 20040716 |
| Accuracy of splitting unscored valdecoxib tablets. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040715 |
| The analgesic effects that underlie patient satisfaction with treatment. | Pain 20040701 |
| Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040701 |
| Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. | Alimentary pharmacology & therapeutics 20040701 |
| Systematic review of the analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain control. | Journal of clinical pharmacy and therapeutics 20040601 |
| Preoperative parenteral parecoxib and follow-up oral valdecoxib reduce length of stay and improve quality of patient recovery after laparoscopic cholecystectomy surgery. | Anesthesia and analgesia 20040601 |
| Parecoxib: new preparation. A NSAID for postoperative pain: no proven advantage. | Prescrire international 20040601 |
| Prostaglandins: modulators of inflammation and cardiovascular risk. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20040601 |
| A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain. | Acta anaesthesiologica Scandinavica 20040501 |
| Parecoxib sodium, an injectable COX-2-specific inhibitor, does not affect unfractionated heparin-regulated blood coagulation parameters. | Journal of clinical pharmacology 20040501 |
| Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040501 |
| Valdecoxib versus rofecoxib in acute postsurgical pain: results of a randomized controlled trial. | Journal of pain and symptom management 20040501 |
| [Etoricoxib (Arcoxia)]. | Revue medicale de Liege 20040501 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040501 |
| Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles. | Journal of medicinal chemistry 20040422 |
| Quantitation of Valdecoxib in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection using liquid-liquid extraction. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040405 |
| Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea. | Journal of pediatric and adolescent gynecology 20040401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040401 |
| [Valdecoxib (Bextra)]. | Revue medicale de Liege 20040401 |
| Collision-induced dissociation of valdecoxib metabolites: a novel rearrangement involving an isoxazole ring. | Journal of mass spectrometry : JMS 20040301 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040301 |
| In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. | Journal of medicinal chemistry 20040212 |
| Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor. | Anesthesia and analgesia 20040201 |
| Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. | Journal of medicinal chemistry 20040129 |
| Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. | Bioorganic & medicinal chemistry letters 20040119 |
| Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat. | Pain 20040101 |
| Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. | Cancer biology & therapy 20040101 |
| Clinical pharmacology of novel selective COX-2 inhibitors. | Current pharmaceutical design 20040101 |
| Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. | Clinical therapeutics 20040101 |
| S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]. | BMC musculoskeletal disorders 20040101 |
| Selective cyclooxygenase-2 inhibitors: similarities and differences. | Scandinavian journal of rheumatology 20040101 |
| A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy. | Drug safety 20040101 |
| Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain. | Drugs 20040101 |
| Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. | American journal of therapeutics 20040101 |
| [Current EULAR data on valdecoxib. New study results of gastrointestinal safety and 'cost effectiveness']. | Krankenpflege Journal 20040101 |
| [Some new drugs: valdecoxib (Betra), voriconazole (Vfend), ezetimide (Ezetrol), teriparatide (Forsteo)]. | Journal de pharmacie de Belgique 20040101 |
| Carbonic anhydrase inhibitors that directly inhibit anion transport by the human Cl-/HCO3- exchanger, AE1. | Molecular membrane biology 20040101 |
| The role of cyclooxygenase selective inhibitors in the gastrointestinal tract. | Current gastroenterology reports 20031201 |
| [Clinical pharmacology of the selective COX-2 inhibitors]. | Der Orthopade 20031201 |
| Evaluation of the efficacy, safety and tolerability of valdecoxib gel (1%) in adult patients with painful inflammatory joint disease. | Journal of the Indian Medical Association 20031201 |
| Measuring dyspepsia-related health in randomized trials: the Severity of Dyspepsia Assessment (SODA) and its use in treatment with NSAIDs and COX-2-specific inhibitors. | Rheumatology (Oxford, England) 20031101 |
| The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors. | Rheumatology (Oxford, England) 20031101 |
| Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial. | Rheumatology (Oxford, England) 20031101 |
| [Pain therapy in rheumatism. After 65 years of age coxibs are the best choice]. | MMW Fortschritte der Medizin 20031016 |
| Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. | Rheumatology (Oxford, England) 20031001 |
| Expression of cyclooxygenase isozymes during morphogenesis and cycling of pelage hair follicles in mouse skin: precocious onset of the first catagen phase and alopecia upon cyclooxygenase-2 overexpression. | The Journal of investigative dermatology 20031001 |
| Development and validation of an automated SPE-LC-MS/MS assay for valdecoxib and its hydroxylated metabolite in human plasma. | Journal of pharmaceutical and biomedical analysis 20030915 |
| Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. | Journal of hypertension 20030901 |
| Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. | Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20030901 |
| Valdecoxib, a COX-2-specific inhibitor, does not affect cardiac repolarization. | Journal of clinical pharmacology 20030901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20030901 |
| [Tolerable pain therapy in rheumatism saves long-term costs. Despite this most COX-2 candidates receive conventional NSAID therapy]. | MMW Fortschritte der Medizin 20030724 |
| Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. | Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20030701 |
| A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. | Alimentary pharmacology & therapeutics 20030701 |
| Efficacy and safety of the first parenteral selective COX-2 inhibitor, parecoxib sodium, in adult patients with postoperative pain. | Journal of the Indian Medical Association 20030701 |
| [Progress in therapy of rheumatism. New coxib works especially fast]. | MMW Fortschritte der Medizin 20030605 |
| Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. | The Journal of thoracic and cardiovascular surgery 20030601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20030601 |
| The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial. | Journal of clinical pharmacology 20030501 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20030501 |
| [Adverse effect-free analgesia. New COX-2 inhibitor is even more selective]. | MMW Fortschritte der Medizin 20030501 |
| Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice. | Drug metabolism and disposition: the biological fate of chemicals 20030401 |
| Characterization of celecoxib and valdecoxib binding to cyclooxygenase. | Molecular pharmacology 20030401 |
| Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. | Anesthesiology 20030401 |
| Valdecoxib-induced toxic epidermal necrolysis in a patient allergic to sulfa drugs. | Pharmacotherapy 20030401 |
| [Coxibs: highly selective cyclooxygenase-2 inhibitors. Part II. Side effects]. | Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20030401 |
| Gateways to clinical trials. March 2003. | Methods and findings in experimental and clinical pharmacology 20030301 |
| Valdecoxib: a review. | Clinical therapeutics 20030301 |
| Determination of valdecoxib and its metabolites in human urine by automated solid-phase extraction-liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030225 |
| Review article: The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. | Alimentary pharmacology & therapeutics 20030215 |
| Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. | Expert opinion on pharmacotherapy 20030201 |
| The COX-2 specific inhibitor, valdecoxib, is an effective, opioid-sparing analgesic in patients undergoing total knee arthroplasty. | Journal of pain and symptom management 20030201 |
| The second generation of COX-2 inhibitors: what advantages do the newest offer? | Drugs 20030101 |
| New warnings for Bextra. | FDA consumer 20030101 |
| Cyclooxygenase-2: from arthritis treatment to new indications for the prevention and treatment of cancer. | Clinical journal of oncology nursing 20030101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20030101 |
| [Pharmacology of cyclooxygenase 2 inhibition]. | Wiener medizinische Wochenschrift (1946) 20030101 |
| COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients. | Arthritis research & therapy 20030101 |
| COX-2: where are we in 2003?--distinction from NSAIDs becoming blurred. | Arthritis research & therapy 20030101 |
| Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population. | The American journal of hospice & palliative care 20030101 |
| Clinical pharmacology of selective COX-2 inhibitors. | International journal of immunopathology and pharmacology 20030101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20021201 |
| The effects of cyclooxygenase isozyme inhibition on incisional wound healing in mouse skin. | The Journal of investigative dermatology 20021101 |
| COX-2 inhibitors and their role in gynecology. | Obstetrical & gynecological survey 20021101 |
| Evaluation of efficacy, safety and tolerability of valdecoxib in osteo-arthritis patients--an Indian study. | Journal of the Indian Medical Association 20021101 |
| Nonsteroidal antiinflammatory drugs and the stomach. | Current opinion in gastroenterology 20021101 |
| Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. | European journal of gastroenterology & hepatology 20021001 |
| [Adverse effects of NSAID are insidious. No pain--despite life threatening gastric hemorrhage]. | MMW Fortschritte der Medizin 20020912 |
| Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. | Drug metabolism and disposition: the biological fate of chemicals 20020901 |
| The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. | Anesthesia and analgesia 20020901 |
| Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. | Rheumatology (Oxford, England) 20020901 |
| A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain. | Anesthesiology 20020901 |
| Gateways to Clinical Trials. | Methods and findings in experimental and clinical pharmacology 20020901 |
| Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. | Obstetrics and gynecology 20020801 |
| Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. | Anesthesiology 20020801 |
| Selecting new drugs for pain control: evidence-based decisions or clinical impressions? | Journal of the American Dental Association (1939) 20020801 |
| Valdecoxib does not impair platelet function. | The American journal of emergency medicine 20020701 |
| Role of COX-2 inhibitors in the evolution of acute pain management. | Journal of pain and symptom management 20020701 |
| Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. | The Journal of family practice 20020601 |
| Right ballpark, wrong base: assessing safety of NSAIDs. | The Journal of family practice 20020601 |
| The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. | Journal of the American Dental Association (1939) 20020501 |
| Valdecoxib (Bextra)--a new cox-2 inhibitor. | The Medical letter on drugs and therapeutics 20020429 |
| Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. | Osteoarthritis and cartilage 20020401 |
| Cox-2 inhibitors: today and tomorrow. | The American journal of the medical sciences 20020401 |
| Nonsteroidal anti-inflammatory drugs, coxibs, and cardio-renal physiology: a mechanism-based approach. | The American journal of cardiology 20020321 |
| Valdecoxib (Pharmacia). | Current opinion in investigational drugs (London, England : 2000) 20020201 |
| Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol. | Anesthesiology 20020101 |
| Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. | American journal of therapeutics 20020101 |
| Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. | American journal of therapeutics 20020101 |
| New COX-2 arthritis drug receives FDA approval. | The journal of gender-specific medicine : JGSM : the official journal of the Partnership for Women's Health at Columbia 20020101 |
| COX-2-selective inhibitors in the treatment of arthritis. | Cleveland Clinic journal of medicine 20020101 |
| Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis. | Cleveland Clinic journal of medicine 20020101 |
| Valdecoxib. | Reviews in gastroenterological disorders 20020101 |
| Valdecoxib. | Drugs 20020101 |
| Etoricoxib. | Drugs 20020101 |
| The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. | Current medical research and opinion 20020101 |
| Mechanism of inhibition of novel COX-2 inhibitors. | Advances in experimental medicine and biology 20020101 |
| A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects. | Journal of clinical pharmacology 20011001 |
| Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis. | Journal of medicinal chemistry 20010927 |
| The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively. | Anesthesia and analgesia 20010901 |
| Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. | Clinical therapeutics 20010901 |
| A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. | The Biochemical journal 20010801 |
| Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. | The Journal of pharmacology and experimental therapeutics 20010201 |
| Parecoxib (parecoxib sodium). | Drugs 20010101 |
| 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. | Journal of medicinal chemistry 20000309 |